HOPA 2018 | Treating GvHD: current challenges and newly approved drugs
Katie Gatwood
Graft versus host disease (GvHD) remains to be one of the leading causes of morbidity and mortality in patients who have undergone bone marrow transplant. Here, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, briefly discusses the challenges with current treatment options for GvHD and gives an update on newly approved drugs that can be used to effectively treat patients. This interview was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
Related videos
10:50
Rivaroxaban for thromboprophylaxis in high-risk cancer patients: CASSINI results
Alok Khorana
6:40
PAUSE: perioperative management of AF patients receiving direct oral anticoagulants
James Douketis
2:31
CASSINI: can we prevent thrombosis in cancer patients who are at risk?
Alok Khorana
0:40
VTE in cancer patients treated with immunotherapy
Alok Khorana
et al.
2:48
Innovative new approaches required for the practical implementation of CAR T-cell therapy
David Irvine
